Cell-free bioproduction of b-cryptoxanthin and zeaxanthin
US-2024368663-A1 · Nov 7, 2024 · US
US9365835B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9365835-B2 |
| Application number | US-201614997277-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 15, 2016 |
| Priority date | Dec 8, 2010 |
| Publication date | Jun 14, 2016 |
| Grant date | Jun 14, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention relates to non-naturally occurring polypeptides useful for preparing armodafinil, polynucleotides encoding the polypeptides, and methods of using the polypeptides. The non-naturally occurring polypeptides of the present invention are effective in carrying out biocatalytic conversion of the (i) 2-(benzhydrylsulfinyl)acetamide to (−)-2-[(R)-(diphenylmethyl)sulfinyl]acetamide (armodafinil), or (ii) benzhydryl-thioacetic acid to (R)-2-(benzhydrylsulfinyl)acetic acid, which is a pivotal intermediate in the synthesis of armodafinil, in enantiomeric excess.
Opening claim text (preview).
What is claimed is: 1. A non-naturally occurring polynucleotide encoding a polypeptide having cyclohexanone monooxygenase (CHMO) activity wherein the amino acid sequence of the polypeptide has at least 95% sequence identity to SEQ ID NO: 136. 2. The polynucleotide of claim 1 , wherein said encoded polypeptide is capable of converting the acid substrate (1b) to compound (2b) (R-enantiomer) or its opposite enantiomer compound (S-enantiomer) with at least 2-fold improved activity relative to the wild-type polypeptide of SEQ ID NO: 2, 3. The polynucleotide of claim 2 , wherein said encoded polypeptide is capable of converting the acid substrate of compound (1b) to the R-enantiomer compound (2b) in at least 50% enantiomeric excess. 4. The polynucleotide of claim 1 , wherein said encoded polypeptide is capable of converting compound (1a) to compound (2a) in at least 75%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% enantiomeric excess under suitable reaction conditions. 5. The polynucleotide of claim 4 , wherein said encoded polypeptide is capable of converting compound (1a) to compound (2a) with an activity increased at least 2-fold, at least 4-fold, at least 10-fold, at least 25-fold, at least 40-fold, or at least 60-fold relative to the activity of the polypeptide of SEQ ID NO: 2 under suitable conditions. 6. The polynucleotide of claim 1 , wherein said encoded polypeptide is capable of converting compound (1b) to compound (2b) in enantiomeric excess under suitable reaction conditions. 7. The polynucleotide of claim 6 , wherein said encoded polypeptide is capable of converting compound (1b) to compound (2b) in at least 75%, at least 85%, at least 90%, at least 95%, at least 98% or at least 99% enantiomeric excess under suitable reaction conditions. 8. The polynucleotide of claim 2 , wherein said encoded polypeptide is capable of converting compound (1b) to compound (2b) with an activity increased at least 2-fold, at least 4-fold, at least 10-fold, at least 25-fold, at least 40-fold, or at least 60-fold relative to the activity of the polypeptide of SEQ ID NO: 38 under suitable reaction conditions. 9. The polynucleotide of claim 2 , wherein said encoded polypeptide is capable of at least 90% or greater conversion of compound (1b) to compound (2b) in 24 h with a substrate loading of about 50 g/L. 10. The polynucleotide of claim 1 , wherein the polynucleotide encodes a polypeptide which comprises the amino acid sequence of SEQ ID NO: 90, 96, 98, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140 or 142.
Amides, e.g. chloramphenicol {or polyamides; Imides or polyimides; Urethanes, i.e. compounds comprising N-C=O structural element or polyurethanes (peptides C12P21/00 or C07K)} · CPC title
with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13 · CPC title
Cyclohexanone monooxygenase (1.14.13.22) · CPC title
Preparation of sulfur-containing organic compounds · CPC title
using catalysts, e.g. selective catalysts · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.